This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Albireo Pharma Management
Management Kriterienprüfungen 2/4
Wichtige Informationen
Ron Cooper
Geschäftsführender
US$6.0m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 9.8% |
| Amtszeit als Geschäftsführer | 7.7yrs |
| Eigentum des Geschäftsführers | 0.2% |
| Durchschnittliche Amtszeit des Managements | 4.2yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.5yrs |
Jüngste Management Updates
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$131m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$6m | US$590k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$136m |
| Mar 31 2021 | n/a | n/a | -US$120m |
| Dec 31 2020 | US$3m | US$570k | -US$108m |
| Sep 30 2020 | n/a | n/a | -US$90m |
| Jun 30 2020 | n/a | n/a | -US$82m |
| Mar 31 2020 | n/a | n/a | -US$78m |
| Dec 31 2019 | US$3m | US$551k | -US$63m |
| Sep 30 2019 | n/a | n/a | -US$71m |
| Jun 30 2019 | n/a | n/a | -US$63m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$4m | US$530k | -US$46m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$28m |
| Mar 31 2018 | n/a | n/a | -US$19m |
| Dec 31 2017 | US$2m | US$460k | -US$24m |
| Sep 30 2017 | n/a | n/a | -US$31m |
| Jun 30 2017 | n/a | n/a | -US$28m |
| Mar 31 2017 | n/a | n/a | -US$20m |
| Dec 31 2016 | US$4m | US$400k | -US$16m |
Vergütung im Vergleich zum Markt: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD3.58M).
Entschädigung vs. Einkommen: Ron's compensation has increased whilst the company is unprofitable.
Geschäftsführer
Ron Cooper (59 yo)
7.7yrs
Amtszeit
US$6,041,334
Vergütung
Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 7.7yrs | US$6.04m | 0.16% $ 1.5m | |
| CFO & Treasurer | 4.4yrs | US$1.71m | 0.066% $ 606.6k | |
| Chief Regulatory Officer | 6.3yrs | US$1.73m | 0.018% $ 161.4k | |
| Co-Founder & VP of Development | no data | keine Daten | keine Daten | |
| Chief Scientific Officer | 15.2yrs | US$1.40m | 0.17% $ 1.6m | |
| Chief Technology Officer | 1.9yrs | keine Daten | keine Daten | |
| Chief Legal Officer | 4.8yrs | keine Daten | 0.016% $ 145.5k | |
| Chief Human Resources Officer | 3.3yrs | keine Daten | 0.027% $ 244.7k | |
| VP & Global Project Head | no data | keine Daten | keine Daten | |
| Chief Commercial Officer | 4yrs | US$1.96m | 0.11% $ 982.0k | |
| Chief Business Officer | 1.3yrs | keine Daten | keine Daten | |
| Chief Medical Officer | less than a year | keine Daten | keine Daten |
4.2yrs
Durchschnittliche Betriebszugehörigkeit
58.5yo
Durchschnittliches Alter
Erfahrenes Management: ALBO's management team is considered experienced (4.2 years average tenure).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 7.5yrs | US$6.04m | 0.16% $ 1.5m | |
| Independent Chairman of the Board | 15.1yrs | US$282.44k | 0.27% $ 2.5m | |
| Independent Director | 6.3yrs | US$266.82k | 0.14% $ 1.3m | |
| Independent Director | 7.4yrs | US$264.94k | 0.13% $ 1.2m | |
| Director | less than a year | keine Daten | keine Daten | |
| Independent Director | less than a year | keine Daten | keine Daten | |
| Independent Director | 4.8yrs | US$249.94k | 0.14% $ 1.3m | |
| Director | less than a year | keine Daten | keine Daten |
5.5yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter
Erfahrener Vorstand: ALBO's board of directors are considered experienced (5.5 years average tenure).